$0.500
-0.338 (-67.53%)收盤時
TCBP 同業比較
In the context of the broader market, TCBP competes directly with industry leaders such as BON and RNAZ. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TCBP's gross margin of N/A stands against BON's 24.00% and RNAZ's N/A. Such benchmarking helps identify whether TC BioPharm Ltd is trading at a premium or discount relative to its financial performance.
Financials
FY2021Q4
YoY:
0.00%
494.67K
Total Revenue
FY2024Q1
YoY:
-17.38%
-3.44M
Operating Profit
FY2024Q1
YoY:
+423.20%
-3.32M
Net Income after Tax
FY2024Q1
YoY:
-64.40%
-1.10
EPS - Diluted
FY2024Q1
YoY:
-21.01%
-2.41M
Free Cash Flow
FY2022Q2
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2022Q2
YoY:
-119.38%
51.87
Net Margin - %
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。